CancerNetwork® Inaugural Face-Off

Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.

Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.

Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.

The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

In a new series from CancerNetwork®, 2 teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.